06 - 0682

August 18, 2006

Representative Bob Gunther, Jobs and Economic Opportunity Policy and Finance Committee Senator Ellen R. Anderson, Jobs, Energy and Community Development Committee Representative Bud Nornes, Higher Education Finance Committee Senator Sandra L. Pappas, Finance Committee – Higher Education Budget Division

Dear Representative Bob Gunther:

Attached is an update on the Minnesota Partnership for Biotechnology and Medical Genomics and an overview of Phase II Partnership expenditures to date as required by Minnesota statute.

Collaboration has resulted in advancing imaging techniques for Alzheimer's disease, pinpointing aggressive forms of prostate cancer, and identifying metabolic factors impacting obesity. Second round research will address other serious health problems including: pancreatic cancer, brain tumors, and cardiovascular, neuromuscular, and autoimmune diseases. We have made other progress, including:

- > 5 research papers published
- > 1 patent application
- > 2 external grant applications
- > Opened joint University of Minnesota/Mayo Clinic Office of Business Development
- ➤ Leveraged industry and philanthropic support, with gifts from Medica (\$5 million) and to the Mayo Clinic for the Johnson Family Center for Genomics of Addiction (\$12 million)
- Major supporter of the BioBusiness Alliance through state-wide outreach

With the \$21.7 million in bonding dollars we received in 2005, we are scheduled to begin occupation into new research space in the Stabile Building in Rochester late this fall. The facility will provide new opportunities to grow our joint research capabilities, fostering further collaboration and creativity.

The Partnership is grateful for the \$15 million in research support provided this past session. The state research investments to date, totaling \$32 million, send a clear message to Minnesotans and those outside of our state that we are leaders in medical research and we stand together to maximize this strength for the benefit of our citizens.

We are very excited about our progress to date and the potential impact of this unique Partnership. We will continue to leverage your state investment to improve the health and economy of Minnesota. If you would like more information about the Partnership, please do not hesitate to contact us or our legislative staff, Marty McDonough at 612.626.7372 or Frank Iossi at 507.284.7230. Thank you.

Sincerely, Handyselva MS

Frank B. Cerra, M.D.

Senior Vice President for Health Sciences

University of Minnesota

Glenn Forbes, M.D.

CEO, Mayo Clinic Rochester

Enclosure:

Cc:

Governor Tim Pawlenty

Acting Commissioner of Employment and Economic Development, Ward Einess

Phase II, Minnesota Partnership for Biotechnology and Medical Genomics June 30, 2006

| U of M Investigator | Mayo Investigator | Title | Budget | Expenditures (through 6/30/06) |
|--|--|---|---|--------------------------------|
| Dr. Rajamani U of M: 1742-530-6691 | Dr. Kaufman MMC: 4091049900-3X1178 | Development of Ulra-Small Sensors for Accurate Quantification of Muscle Forces in Neuromuscular Diseases | \$699,121 \$312,641 \$386,480 | \$80 \$0 |
| Dr. Largaespada U of M: 1742-652-6214 | Dr. Jenkins MMC: 6089109900-3X1174 | Neuro-Oncology Genetics | \$990,357 \$544,557 \$445,800 | \$17,001 \$0 |
| Dr. Dong U of M: 1929-343-6055 | Dr. Pang MMC: 6421109900-3X1176 | Selective, Small-Molecule Inhibitors of JNK2 as Anti-Cancer Drugs | \$1,500,000 \$755,000 \$745,000 | \$352 \$20,961 |
| Dr. Tsukayama U of M: | Dr. Wengenack MMC: 6082019900-3X1177 | Medical Genomics Applied to an Ancient Disease: Real-time PCR for the Diagnosis and Direct Drug Susceptibility Testing of Tuberculosis | \$400,75 9 \$253,300 \$147,459 | \$53 |
| Dr. Peterson U of M: 1742-636-7688 | Dr. Reed MMC: 5583229900-3X1170 | Biomarker Discovery in Autoimmunity | \$1,332,197 \$672,750 \$659,447 | \$34,243 \$16,574 |
| Dr. Steve Patterson U of M: 1742-875-6001 | Dr. Daniel Billadeau MMC: 5154089900-3X1175 | Combinatorial Based Chemistry and High Throughput Screening Methods to Identify Rac GTPase Inhibitors | \$1,123,525 \$774,344 \$349,181 | \$24,924 \$0 |

r

Phase II, Minnesota Partnership for Biotechnology and Medical Genomics June 30, 2006

| U of M Investigator | Mayo Investigator | Title | Budget | Expenditures (through 6/30/06) |
|--|---|--|-------------------------------------|--------------------------------|
| Dr. William Oetting U of M: 1929-636-7685 | Dr. Fernando Cosio | Identifying factors influencing the survival of kidney allografts by genomic and protemic analysis | \$1,210,793 | |
| | MMC: 5571369900-3X1179 | | \$717,600 \$493,193 | \$12,911 \$0 |
| Dr. Marilyn Carroll U of M: 1929-645-6390 | Dr. Stephen Brimijoin MMC: 6421209900-3X1171 | Towards a Gene Therapy for Cocaine Addiction | \$482,438 \$212,636 \$269,802 | \$4,427 \$31,161 |
| | | Progenitor Cells as Biomarkers: Developing Diagnostic and Prognostic Profiles | | |
| Dr. Doris Taylor U of M: | Dr. Amir Lerman | for Cardiovascular Disease | \$737,029 \$440,711 | |
| | MMC: 5526729900 | | \$296,318 | \$0 |
| Dr. Vivek Kapur U of M: 1742-628-6248 | Dr. David Smith MMC: 4146089900-3X1183 | MINGEN-MINnesota GENomics Infrastructure Initiative | \$1,500,000 \$1,500,000 | \$13,661 \$0 |
| Dr. Caroline Wilmot U of M: 1742-439-6406 | Dr. James Thompson | X-Ray crystanography infrastructure; a Mayo Clinic/University of Minnesota Partnership to solve novel macromolecular structures important to human health and disease | \$845,626 \$845,626 | \$165 |
| Dr. John Wagner U of M: 1742-846-9000 | Dr. Larry Pease | Development and Manufacturing of Biotherapeutic Proteins | \$1,660,000 \$1,660,000 | \$0 |
| Dr. Gary Nelsestuen U of M: | Dr. H. Robert Bergen, III | Instrumentation and Bioinformatics for Biomarker Discovery | \$1,087,850 \$1,087,850 | |
| Dr. Birali Runesha U of M: | Dr. Jean-Pierre Kocher | Collaborative Workflow Environment for Bioinformatics: Implementation and Integration of Data Workflow Technology to Accelerate the Development and Deployment of Customized Bioinformatics Applications | \$930,000 | |
| | | | | |



Phase II, Minnesota Partnership for Biotechnology and Medical Genomics June 30, 2006

| U of M Investigator | Mayo Investigator | Title | Budget | Expenditures (through 6/30/06) |
|----------------------------|-------------------|----------------|------------------------|-----------------------------------|
| Dr. Mark Paller U of M: | Dr. Eric Wieben | Other Expenses | \$500,305 \$500,305 | |
| Total | | | \$15,000,000 | \$176,513 |

